NAMCP Slideshow

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms, known as hot flashes, compared with placebo across body mass index (BMI) and smoking status subgroups.

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin in a new meta-analysis.

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual meeting.